Rofecoxib is a COX-2-selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis...

reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class. After several COX-2–inhibiting...

became the building-block for synthesis of COX-2 inhibitors. Celecoxib and rofecoxib, the first COX-2 inhibitors to reach market, were based on DuP-697. It...

heart attack. As a result, certain COX-2 selective inhibitors—such as rofecoxib—are no longer used due to the high risk of undiagnosed vascular disease...

complicated upper gastrointestinal events are similar between two groups. Like rofecoxib's VIGOR trial, the MEDAL Program was also criticized, this time due to...

(traditional NSAIDs block both versions in general). These drugs (such as rofecoxib, celecoxib, and etoricoxib) are equally effective analgesics when compared...

advice to physicians regarding celecoxib's safety. The COX-2 inhibitor rofecoxib (Vioxx) was removed from the market in 2004 due to its risk. Like all...

of increased risks of heart attacks with the selective COX-2 inhibitor rofecoxib in 2004, attention has focused on all the other members of the nonsteroidal...

effective for a small number of people. The COX-2 selective inhibitor rofecoxib was removed from the market in 2004, as cardiovascular events were associated...

Ramelteon Rasagiline Reboxetine Ribavirin Rimonabant Risperidone Rivastigmine Rofecoxib Ropinirole Rotigotine Rufinamide Selegiline Sertraline Sevoflurane Sulpiride...